ET
ORIC icon

Entropy Technologies’s Oric Pharmaceuticals ORIC Stock Holding History

Entropy Technologies’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,799
Closed -$186K – 1090
2025
Q4 		$186K Buy
+22,799
New +$262K 0.01% 810

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Entropy Technologies's ORIC Position: Q1 2026 in Review

Entropy Technologies sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 22,799 shares — an estimated $186K sold.

Entropy Technologies first reported a position in ORIC in Q4 2025 and held it in 1 quarter. The position peaked at $186K in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Entropy Technologies reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Entropy Technologies sold 22,799 Oric Pharmaceuticals shares in Q1 2026, an estimated $186K.
  • Entropy Technologies first reported a position in Oric Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Entropy Technologies's Oric Pharmaceuticals position peaked at $186K in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.